Core Pharmaceutical Leader Receives Good News Again - UniPharmaceuticals (00512.HK) TLX591 Approved to Join International Multicenter Phase III Clinical Trial or Modify mCRPC Treatment Standard

Wisdom Financial News APP learned that the leading company in nuclear medicine is once again in good shape! Since May, Uni-Bio Science Group Limited (00512.HK) has made continuous progress in the nuclear medicine sector. Following the acquisition of the "Radiation Safety Permit" for its global leading nuclear medicine base and the official early approval by the US FDA for the new indication of treating unresectable hepatocellular carcinoma (HCC) with SIR-Spheres yttrium [90Y] microsphere injection (EasyGrant), the company has made another significant breakthrough in global innovative nuclear medicine research and development.